Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathways. (2023). Brazilian Journal of Pharmaceutical Sciences, 59, e23002. https://doi.org/10.1590/s2175-97902023e23002